Cargando…

Impact of Rheumatoid Arthritis Disease Activity Test on Clinical Practice

BACKGROUND: Variability exists in the assessment of disease activity in rheumatoid arthritis (RA) patients that may affect quality of care. OBJECTIVES: To measure the impact on quality of care of a Multi-Biomarker Disease Activity (MBDA) test that quantitatively assesses RA disease activity. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Peabody, John W., Strand, Vibeke, Shimkhada, Riti, Lee, Rachel, Chernoff, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646735/
https://www.ncbi.nlm.nih.gov/pubmed/23667587
http://dx.doi.org/10.1371/journal.pone.0063215
_version_ 1782268633025609728
author Peabody, John W.
Strand, Vibeke
Shimkhada, Riti
Lee, Rachel
Chernoff, David
author_facet Peabody, John W.
Strand, Vibeke
Shimkhada, Riti
Lee, Rachel
Chernoff, David
author_sort Peabody, John W.
collection PubMed
description BACKGROUND: Variability exists in the assessment of disease activity in rheumatoid arthritis (RA) patients that may affect quality of care. OBJECTIVES: To measure the impact on quality of care of a Multi-Biomarker Disease Activity (MBDA) test that quantitatively assesses RA disease activity. METHODS: Board-certified rheumatologists without prior experience with the MBDA test (N = 81) were randomized into an intervention or control group as part of a longitudinal randomized-control study. All physicians were asked to care for three simulated RA patients, using Clinical Performance and Value (CPV™) vignettes, in a before and after design. CPV™ vignettes have been validated to assess the quality of clinical practice and identify variation in care. The vignettes covered all domains of a regular patient visit; scores were determined as a percentage of explicit predefined criteria completed. Three vignettes, representing typical RA cases, were administered each round. In the first round, no physician received information about the MBDA test. In the second round, only physicians in the intervention group were given educational materials about the test and hypothetical test results for each of the simulated patients. The outcome measures were the overall quality of care, disease assessment and treatment. RESULTS: The overall quality scores in the intervention group improved by 3 percent (p = 0.02) post-intervention compared with baseline, versus no change in the control group. The greatest benefit in the intervention group was to the quality of disease activity assessment and treatment decisions, which improved by 12 percent (p<0.01) compared with no significant change in the control group. The intervention was associated with more appropriate use of biologic and/or combination DMARDs in the co-morbidity case type (p<0.01). CONCLUSIONS: Based on these results, use of the MBDA test improved the assessment and treatment decisions for simulated cases of RA and may prove useful for rheumatologists in clinical practice.
format Online
Article
Text
id pubmed-3646735
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36467352013-05-10 Impact of Rheumatoid Arthritis Disease Activity Test on Clinical Practice Peabody, John W. Strand, Vibeke Shimkhada, Riti Lee, Rachel Chernoff, David PLoS One Research Article BACKGROUND: Variability exists in the assessment of disease activity in rheumatoid arthritis (RA) patients that may affect quality of care. OBJECTIVES: To measure the impact on quality of care of a Multi-Biomarker Disease Activity (MBDA) test that quantitatively assesses RA disease activity. METHODS: Board-certified rheumatologists without prior experience with the MBDA test (N = 81) were randomized into an intervention or control group as part of a longitudinal randomized-control study. All physicians were asked to care for three simulated RA patients, using Clinical Performance and Value (CPV™) vignettes, in a before and after design. CPV™ vignettes have been validated to assess the quality of clinical practice and identify variation in care. The vignettes covered all domains of a regular patient visit; scores were determined as a percentage of explicit predefined criteria completed. Three vignettes, representing typical RA cases, were administered each round. In the first round, no physician received information about the MBDA test. In the second round, only physicians in the intervention group were given educational materials about the test and hypothetical test results for each of the simulated patients. The outcome measures were the overall quality of care, disease assessment and treatment. RESULTS: The overall quality scores in the intervention group improved by 3 percent (p = 0.02) post-intervention compared with baseline, versus no change in the control group. The greatest benefit in the intervention group was to the quality of disease activity assessment and treatment decisions, which improved by 12 percent (p<0.01) compared with no significant change in the control group. The intervention was associated with more appropriate use of biologic and/or combination DMARDs in the co-morbidity case type (p<0.01). CONCLUSIONS: Based on these results, use of the MBDA test improved the assessment and treatment decisions for simulated cases of RA and may prove useful for rheumatologists in clinical practice. Public Library of Science 2013-05-07 /pmc/articles/PMC3646735/ /pubmed/23667587 http://dx.doi.org/10.1371/journal.pone.0063215 Text en © 2013 Peabody et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Peabody, John W.
Strand, Vibeke
Shimkhada, Riti
Lee, Rachel
Chernoff, David
Impact of Rheumatoid Arthritis Disease Activity Test on Clinical Practice
title Impact of Rheumatoid Arthritis Disease Activity Test on Clinical Practice
title_full Impact of Rheumatoid Arthritis Disease Activity Test on Clinical Practice
title_fullStr Impact of Rheumatoid Arthritis Disease Activity Test on Clinical Practice
title_full_unstemmed Impact of Rheumatoid Arthritis Disease Activity Test on Clinical Practice
title_short Impact of Rheumatoid Arthritis Disease Activity Test on Clinical Practice
title_sort impact of rheumatoid arthritis disease activity test on clinical practice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646735/
https://www.ncbi.nlm.nih.gov/pubmed/23667587
http://dx.doi.org/10.1371/journal.pone.0063215
work_keys_str_mv AT peabodyjohnw impactofrheumatoidarthritisdiseaseactivitytestonclinicalpractice
AT strandvibeke impactofrheumatoidarthritisdiseaseactivitytestonclinicalpractice
AT shimkhadariti impactofrheumatoidarthritisdiseaseactivitytestonclinicalpractice
AT leerachel impactofrheumatoidarthritisdiseaseactivitytestonclinicalpractice
AT chernoffdavid impactofrheumatoidarthritisdiseaseactivitytestonclinicalpractice